Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mefloquine Prophylaxis for COVID-19 Contacts
NCT04847661Phase 3Completed
- Sponsor
- Helwan University
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mefloquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Helwan University. Primary endpoints: Rate of COVID-19 infection at 2 weeks and Severity of COVID-19 disease at 2 weeks. Started Mar 2021; status: completed.
02
Drugs
mefloquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04847661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847661.